Latest News about CMPS
Recent news which mentions CMPS
   The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
   
  October 11, 2023
  Tickers 
   CMPS
  
  
  From Benzinga
 
   Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
   
  
  
  October 06, 2023
  From Benzinga
 
   COMPASS Pathways Is Accelerating Patient Access To Evidence-Based Innovation In Mental Health Care
   
  
  
  October 05, 2023
  From Benzinga
 
   Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
   
  
  
  October 02, 2023
  From Benzinga
 
   Don’t Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher
   
  
  
  September 27, 2023
  From InvestorPlace
 
   Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
   
  
  
  September 26, 2023
  From Benzinga
 
   Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
   
  
  
  September 18, 2023
  From Benzinga
 
   One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
   
  
  
  September 18, 2023
  From Benzinga
 
   Swedish Foundation Supports Mental Health Innovation With New €3M Psychedelic Science Initiative
   
  September 13, 2023
  Tickers 
   CMPS
  
  
  From Benzinga
 
   NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
   
  
  
  September 12, 2023
  From Benzinga
 
   What's Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field
   
  September 12, 2023
  Tickers 
   CMPS
  
  
  From Benzinga
 
   Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
   
  
  
  September 11, 2023
  From Benzinga
 
   Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
   
  September 06, 2023
  Tickers 
   CMPS
  
  
  From Benzinga
 
   Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
   
  
  
  September 05, 2023
  From Benzinga
 
   Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
   
  
  
  August 28, 2023
  From Benzinga
 From Motley Fool
 
   Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
   
  
  
  August 21, 2023
  From Benzinga
 
   COMPASS' Securities Purchase Agreement Is Big News
   
  
  
  August 18, 2023
  From Benzinga
 
   Up To $285M In Financing: COMPASS Pathways' Private Placement Backed By 'Select Group' Of Investors
   
  August 16, 2023
  Tickers 
   CMPS
  
  
  From Benzinga
 
   Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
   
  
  
  August 14, 2023
  From Benzinga
 
   Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA
   
  
  
  August 10, 2023
  From Benzinga
 
   Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript
   
  August 04, 2023
  Tickers 
   CMPS
  
  
  From Motley Fool
 
   COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And 'Strong Progress Across The Business'
   
  
  
  August 03, 2023
  From Benzinga
 
   Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
   
  
  
  August 03, 2023
  From Benzinga
 From Benzinga
 Tickers 
   CMPS
  
  
  From Motley Fool
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
